Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy.

Renal cell carcinomas belong to the small group of tumors that are able to induce antitumor responses. Here we describe two general types of cytotoxic effector lymphocytes that can eliminate autologous tumor cells and discuss the role that major histocompatibility complex encoded molecules play in governing their specificities. Improved understanding of the cellular and molecular basis of renal cell carcinoma recognition opens new avenues of research with the potential to develop better immunotherapies for patients with metastatic disease.
AuthorsD J Schendel, R Oberneder, C S Falk, P Jantzer, S Kressenstein, B Maget, A Hofstetter, G Riethmüller, E Nössner
JournalJournal of molecular medicine (Berlin, Germany) (J Mol Med (Berl)) Vol. 75 Issue 6 Pg. 400-13 (Jun 1997) ISSN: 0946-2716 [Print] GERMANY
PMID9231880 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
  • Antigen-Antibody Reactions
  • Carcinoma, Renal Cell (therapy)
  • Humans
  • Immunotherapy
  • Kidney Neoplasms (therapy)
  • Killer Cells, Lymphokine-Activated (immunology)
  • Major Histocompatibility Complex (immunology)
  • T-Lymphocytes, Regulatory (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: